Trimeris
reported after the markets closed Tuesday.
However, the sales figure is a drop from the $62.9 million total Trimeris (Nasdaq: TRMS) reported for the fourth quarter of 2005. That was the company's first profitable quarter since going public.
Sales were sufficient in the first quarter that the company reaffirmed guidance for expected profitability in 2006.
Fuzeon produced $27.4 million in revenue in the U.S. and Canada, up 17 percent from 2005. However, international sales reached $28 million, a 47 percent jump from 2005.
"Fuzeon achieved strong double digit sales growth across all major markets when comparing first quarter 2005 with first quarter 2006 performance. In North America, both new and total prescription levels demonstrated strong underlying demand, growing 19 percent and 10 percent respectively," said Steven Skolsky, chief executive officer of Trimeris. "These results give me confidence in reiterating our 2006 North American sales guidance of $140 million to $150 million, and in our expectation for sustaining our profitability for 2006."
Sales of Fuzeon are handled by Roche, Trimeris' drug development partner.
Copyright 2024 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
